tbuckley/cabot-search huggingface dataset:
A phase II trial of perioperative chemotherapy with folinic acid, 5-fluorouracil, and oxaliplatin in potentially resectable gastric cancer with regional lymph node metastasis
Authors: S. Im, S. Kim, J. Kim, H. Lee, M. Kim, S. Kim, W. Kang, H. Yang, I. Song, Y. Bang
Journal: Journal of Clinical Oncology (2007)

4602 Background: Peri-operative chemotherapy in operable advanced gastric cancer (AGC) is still in a controversial area. Results from MAGIC trial suggest that a peri-operative regimen of ECF (epirubicin, cisplatin, 5-FU) decreased tumor size and significantly improved PFS and OS in patients with operable AGC (NEJM 355: 11, 2006). The aim of this study was to evaluate the efficacy and toxicity of folinic acid (FA), infusional 5-fluorouracil (5-FU), and oxaliplatin (modified FOLFOX6), administered every 2 wks in potentially operable AGC with regional lymph node (LN) metastasis. Methods: Previously untreated gastric adenocarcinoma patients with measurable LN on CT scan (clinical stage: cT2 or cT3, N+) were eligible. Staging also included a PET-CT and endoscopic ultrasonography (EUS). Patients received 4 cycles of neoadjuvant therapy with FA 100 mg/m 2 (2-hr i.v.), 5-FU 2.4 g/m 2 (46-hr continuous infusion), and oxaliplatin 100 mg/m 2 (2-hr i.v.), followed by curative radical surgery including D2 dissection and 4 cycles of adjuvant modified FOLFOX6. Clinical responses were assessed by RECIST using CT scan before surgery and early metabolic responses were assessed by PET-CT after 2 cycles of chemotherapy. Results: Thirty-one patients were enrolled from Oct. 2004 to Nov. 2006 and currently, 29 of them are evaluable for response. Median age was 56 yrs (range, 35–69). Most patients had EUS T3N1or2 designation. Of 29 evaluable patients, PR were observed in 19 (66%), SD in 9 (31%), and PD in 1 (3%) patient. Early metabolic responses (SUV decrement = 35% by PET-CT) were significantly correlated with conventional radiographic response (p=0.037). The R0 resection rate was 90% and pathologic CR was 7%. Median follow-up duration was 11.8 mo. and median PFS has not been reached yet. Total 219 cycles were administered. G3/4 neutropenia occurred in 6 cycles (3.0%). Nausea G3/4 occurred in 1 cycle (0.5%) and diarrhea in 1 cycle (0.5%). There were no cases of peripheral neuropathy G3/4 or febrile neutropenia G3/4. Conclusions: Peri-operative chemotherapy with modified FOLFOX6 is very effective and feasible in patients with potentially resectable AGC with regional LN metastasis. Early response can be predicted by PET-CT. No significant financial relationships to disclose.
Abstract 10983: Complementary Relationship of Right Ventricular Contraction Between Longitudinal and Radial Directions
Authors: Ikuo Hashimoto, Hiroyasu Nakagawa, Kou Shibata, Hisashi Kaneda, Kazuyoshi Saito, Kazuhiro Watanabe, Sayaka Ozawa, Fukiko Ichida, Naoki Yoshimura
Journal: Circulation (2012)

Background: Unlike to left ventricular contraction, the mechanism of right ventricular contraction has been unclear because of its complex geometry. Right ventricular cavity changes during systole ...
Regional screening network for characterization of the molecular epidemiology of non-small cell lung cancer (NSCLC) and implementation of personalized treatment.
Authors: Thomas Zander, Lukas Carl Heukamp, Marc Christiaan Allardt Bos, Jana Fassunke, Christian Mattonet, Sabine Merkelbach-Bruse, Yon-Dschun Ko, Andreas Schlesinger, Michael Brockmann, Monika Serke, Ulrich Gerigk, Khosro Hekmat, Walburga Engel-Riedel, Erich Stoelben, Marcel Reiser, Holger Schulz, Stephan H. Schmitz, Konrad Frank, Reinhard Buettner, Juergen Wolf
Journal: Journal of Clinical Oncology (2012)

CRA10529 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Monday, June 4, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.
Abstract 15008: Androgens Ameliorate Age-Related Impairment in Ischemia-Mediated Neovascularization by Enhancement of Androgen-Receptor Dependent, Endothelial Progenitor Cell (EPC)-Mediated Vasculogenesis
Authors: Yuen Ting Lam, Laura Lecce, Sui Ching Yuen, David J Handelsman, Richard Karas, Martin K Ng
Journal: Circulation (2014)

Introduction: Increasing evidence indicates that androgen regulates angiogenesis. In aging men, a progressively decline in circulating androgens is coincident with cardiovascular disease. This study elucidated the role of androgens in ischemia-mediated neovascularization in young and old animals. Methods: In a murine hindlimb ischemia (HLI) model, dihydrotestosterone (DHT) or placebo (P) was implanted in young (2-month), androgen receptor knockout (ARKO) (2-month) and old (24-month) mice post-HLI. The blood flow recovery was monitored by Laser Doppler. Bone marrow EPCs were ex vivo cultured for DHT treatment. Results: Aging was associated with marked impairment in ischemic recovery after HLI. DHT augmented blood flow recovery in young mice and significantly attenuated age-related impairment of ischemic recovery in old mice after HLI (young; DHT vs. P, 0.92±0.18 vs. 0.72±0.21, p<0.05. Old; DHT vs. P, 0.34±0.05 vs. 0.16±0.05, p<0.01). In old mice, DHT augmented EPC proliferation (DHT vs. P, 5.64±1.12 vs. 3....
Effects and Functional Mechanisms of Photosan-Loaded Nanoparticle-Mediated Photodynamic Therapy on Ht29 Cells
Authors: Kuijie Liu, Zhongqiang zhang, Li Xiong, Yu Wen, Yuanhan Li, Hua Zhao, Yang Sun, Jane Yu, Hongliang Yao
Journal: Annals of Oncology (2014)
A Distributed Network for Intensive Longitudinal Monitoring in Metastatic Triple-Negative Breast Cancer
Authors: C. Anthony Blau, Arturo B. Ramirez, Sibel Blau, Colin C. Pritchard, Michael O. Dorschner, Stephen C. Schmechel, Timothy J. Martins, Elisabeth M. Mahen, Kimberly A. Burton, Vitalina M. Komashko, Amie J. Radenbaugh, Katy Dougherty, Anju Thomas, Christopher P. Miller, James Annis, Jonathan R. Fromm, Chaozhong Song, Elizabeth Chang, Kellie Howard, Sharon Austin, Rodney A. Schmidt, Michael L. Linenberger, Pamela S. Becker, Francis M. Senecal, Brigham H. Mecham, Su-In Lee, Anup Madan, Roy Ronen, Janusz Dutkowski, Shelly Heimfeld, Brent L. Wood, Jackie L. Stilwell, Eric P. Kaldjian, David Haussler, Jingchun Zhu
Journal: Journal of the National Comprehensive Cancer Network (2016)

Accelerating cancer research is expected to require new types of clinical trials. This report describes the Intensive Trial of OMics in Cancer (ITOMIC) and a participant with triple-negative breast cancer metastatic to bone, who had markedly elevated circulating tumor cells (CTCs) that were monitored 48 times over 9 months. A total of 32 researchers from 14 institutions were engaged in the patient's evaluation; 20 researchers had no prior involvement in patient care and 18 were recruited specifically for this patient. Whole-exome sequencing of 3 bone marrow samples demonstrated a novel ROS1 variant that was estimated to be present in most or all tumor cells. After an initial response to cisplatin, a hypothesis of crizotinib sensitivity was disproven. Leukapheresis followed by partial CTC enrichment allowed for the development of a differential high-throughput drug screen and demonstrated sensitivity to investigational BH3-mimetic inhibitors of BCL-2 that could not be tested in the patient because requests to the pharmaceutical sponsors were denied. The number and size of CTC clusters correlated with clinical status and eventually death. Focusing the expertise of a distributed network of investigators on an intensively monitored patient with cancer can generate high-resolution views of the natural history of cancer and suggest new opportunities for therapy. Optimization requires access to investigational drugs.
Utility of a novel serum tumor biomarker HE4 in patients with uterine cancer
Authors: R. G. Moore, A. K. Brown, C. M. Miller, D. Badgwell, Z. Lu, T. Verch, J. W. Allard, C. O. Granai, R. Bast, K. Lu
Journal: Journal of Clinical Oncology (2006)

5036 Background: Approximately 40,880 new cases of uterine cancer are diagnosed in the U.S. annually resulting in 7,310 deaths. Uterine cancer is surgically staged and 75% of patients present with stage I disease. Patients with stage I tumors with intermediate to high risk factors have a recurrence rate of 20 to 30%. Serum CA125 is elevated in 75% of patients with advanced stage disease and in only 17% of patients with early stage disease. The use of CA125 for the detection of recurrent disease is limited at best. Only 25% of patients with asymptomatic recurrent disease have an elevated CA125. A better marker indicating early recurrent disease is needed. The objective of this study was to examine the value of a novel serum tumor marker HE4 in endometrial cancer. Methods: Serum samples from two prospective IRB approved studies at two institutions were analyzed to compare HE4 with CA125 in patients who had surgical staging for uterine cancer. Normal controls were obtained from healthy patients. Informed consent was obtained from all patients and blood samples were drawn pre-operatively. HE4 and CA125 levels were determined using assays from Fujirebio Diagnostic Inc. ROC curves were constructed for each tumor marker and the sensitivity at a set specificity of 95% was determined. Results: Serum from 156 controls and 233 patients with surgically staged endometrial cancer; (151 stage I, 21 stage II, 47 stage III and 14 stage IV) were examined. The area under the ROC curves (ROC-AUC) for HE4 and CA125 were determined and compared ( Table1 ). At 95% specificity, the sensitivity for differentiation of controls versus all stages was 44.9% for HE4 compared to 25.2% for CA125 (p = 0.0001). For stage I cases, HE4 showed an improvement in the sensitivity of 20.5% compared to CA125 (37.1% vs 16.6%, p = 0.0001). Conclusions: HE4 is elevated in all stages of endometrial cancer and has a greater sensitivity for discrimination from normal controls compared to CA125. As well, HE4 is elevated in early stage endometrial cancer and should be investigated as a marker for early recurrent disease. [Table: see text] [Table: see text]
Single preoperative intravesical instillation of electromotive mitomycin-C for primary non-muscle-invasive bladder cancer: A prospective randomized trial.
Authors: S. M. Di Stasi, C. Verri, G. Capelli, M. Brausi, G. Leprini, M. Casilio, G. Zampa
Journal: Journal of Clinical Oncology (2010)

4543 Background: We compared the effects of one immediate pretransurethal resection (TUR) intravesical electromotive (EMDA) mitomycin-C (MMC) instillation with one early post-TUR intravesical passive diffusion (PD) MMC instillation and TUR alone in patients with non-muscle invasive bladder cancer (NMIBC). Methods: From 1994 to 2003, 352 elegible patients with primary NMIBC were randomized into 3 groups who underwent TUR alone (n=116); TUR plus one immediate instillation of 40 mg PD/MMC with a dwell time of 60 minutes (n=119); or one immediate pre-TUR instillation of 40 mg EMDA/MMC with 20 mA electric current for 30 minutes (n=117). Patients with intermediate and high risk NMIBC underwent adjuvant intravesical therapy. The primary end point was disease-free interval. All clinical analyses were performed on an intent to treat basis. Results: During a median followup of 85.4 months there was recurrence in 188/352 patients (53.4%), including 74 (63.8%) TUR/alone group, 70 (58.8%) in PD/MMC post-TUR group and 44 (37.6%) in EMDA/MMC pre-TUR group (p=<0.001). In 30/352 patients (8.5%) with low risk disease, only 1 (3.3%), in EMDA/MMC pre-TUR group, had recurrence (p=0.409). In 225/352 patients (63.9%) with intermediate risk disease, 119 (52.9%) had recurrence, 47/75 (62.7%) in TUR/alone group, 46/77 (59.7%) in PD/MMC post-TUR group and 26/73 (35.6%) in EMDA/MMC pre-TUR group (p=0.001). In 97/352 patients (27.6%) with high disease, 68 (70.1%) had recurrence, 27/33 (84.4%) in TUR/alone group, 24/32 (75.0%) in PD/MMC post-TUR group and 17/33 (51.5%) in EMDA/MMC pre-TUR group (p=0.012). Overall median disease-free interval was 12.9 months for TUR/alone group, 16.4 months for PD/MMC post-TUR group and 56.9 for EMDA/MMC pre-TUR group (p=<0.001). In the PD/MMC post-TUR group 43 patients (36.1%) had bladder symptoms and 28 (23.5%) had treatment discontinued because of pain or bladder spasms. No side effects were observed in EMDA/MMC pre-TUR group. Conclusions: In patients with NMIBC one immediate pre-TUR intravesical EMDA/MMC instillation enhances the disease-free interval compared with one immediate post-TUR intravesical PD/MMC instillation and TUR alone. No significant financial relationships to disclose.
Abstract 18663: Clinical Risk Profile of Stroke in Hypertrophic Cardiomyopathy: A Case-Matched Study from the Nationwide Inpatient Survey (NIS)
Authors: Danika Vercimak, Sue Duval, Renuka Jain
Journal: Circulation (2012)

Introduction: Ischemic stroke complicates hypertrophic cardiomyopathy (HCM), but little is known about the epidemiology of stroke in patients(pts) with HCM as opposed to stroke in pts without HCM. Methods: Using administrative data from the Nationwide Inpatient Sample (NIS) in years 2000-2009, we analyzed all cases of acute ischemic stroke and transient ischemic attack (TIA) requiring hospitalization in patients with HCM. We matched these pts by year of admission with a random sample of stroke and TIAs in non-HCM pts. Results: We analyzed 540 cases of acute stroke/TIA in pts with HCM compared to 2164 cases of acute stroke/TIA in pts without HCM. Mean age and prevalence of hypertension were similar in both groups (Table). In this population of stroke pts, atrial fibrillation was 3.3 (95% CI 2.6-4.0) times more common in HCM group than non-HCM group. Additional characteristics more common in HCM group were female gender (OR 1.7, 95% CI 1.4-2.0), congestive heart failure (OR 2.0, 95% CI 1.5-2.6), and valvular heart disease (OR 3.4, 95% CI 2.6-4.4). Length of hospital stay was one day longer (5.4 days vs. 4.2 days, p&lt;.0001) and routine discharge to home was less frequent (51.9% vs. 61.1%, p&lt;.01) in the HCM compared to non-HCM group. There was no change in which outcomes were statistically significant after adjusting for age and comorbidity score. However, after controlling for the characteristics that differ significantly between HCM and non-HCM groups in Table 1, routine discharge became statistically non-significant (p&lt;0.07). This was due to the addition of atrial fibrillation to the model. There was no significant difference in in-hospital mortality after stroke. Conclusions: In the largest case series accumulated of stroke/TIAs in HCM patients, key differences were seen in the clinical risk profile and outcomes of stroke compared to non-HCM controls. This suggests that a unique approach should be taken in dealing with patients with HCM who suffer from stroke.
Association of topoisomerase-1 (Topo1) with the efficacy of chemotherapy in a randomized trial for advanced colorectal cancer patients (FOCUS)
Authors: M. S. Braun, S. D. Richman, J. W. Adlard, C. Daly, F. Turner, J. Barrett, M. Parmar, P. Selby, P. Quirke, M. T. Seymour
Journal: Journal of Clinical Oncology (2006)

10009 Background: We have assessed potential predictive markers of the efficacy of irinotecan and oxaliplatin in advanced CRC patients randomized to fluorouracil (FU), FU+irinotecan (Ir) or FU+oxaliplatin (Ox). Methods: Pathology specimens were retrieved from 1281 patient in the FOCUS trial (ASCO 05 #3518). Normal and tumor DNA were extracted and tissue microarrays were made for immunohistochemistry (IHC). The following factors were assessed for effect on failure-free survival (FFS) with first-line therapy: IHC for MLH1, MSH2, P53, Topo1, ERCC1, MGMT, and COX2; DNA polymorphisms in GSTP1 (105Val), ABCB1 (C3435T), XRCC1 (Q399R), ERCC2 (K751Q), and UGT1A1*28. Results: Among 823 patients assessable for Topo1 IHC, we observed highly significant heterogeneity (interaction) of treatment effect in relation to Topo1 staining intensity (p=0.008, see table). 489 patients (59%) had moderate or high Topo1 expression; these patients derived highly significant benefit from 1 st -line chemotherapy with either Ir or Ox. In contrast, the 334 (41%) patients with low Topo1 IHC expression showed no evidence of benefit from the addition of either Ir or Ox compared with FU alone (HR 1 and 0.9 respectively). When patients receiving FU alone are considered separately, low Topo1 expression was associated with significantly better FFS (HR 0.7 (0.6–0.9)). The other 11 molecular markers showed no significant interactions with treatment received (p values for interaction all &gt; 0.1). Conclusions: We have identified a subgroup of 41% patients (with low Topo1 expression) for whom treatment outcome with FU alone is superior, but who appear to gain no benefit from the addition of Ir or Ox. We believe this to be the first demonstration in a large randomized trial of a genuinely predictive molecular marker. If verified in an independent dataset, this information could be used to select patients who can be safely treated with FU alone, or together with alternative additional agents. [Table: see text] No significant financial relationships to disclose.
Nursing support program to decrease or prevent side effects of pegylated liposomal doxorubicin (PLD) in patients with recurrent epithelial ovarian cancer (REOC)
Authors: N. Grenier, V. Lebel, M. Gill, K. Mitchinson, M. Foster, S. Lewis, K. Sebborn, A. Rodgers, J.-F. Pouliot, T. Mullen
Journal: Journal of Clinical Oncology (2005)

8198 Background: A significant long-term survival with PLD compared to topotecan was recently reported in a phase III randomized study of women with REOC (Gyn. Oncol. 2004). PLD is known to be relatively less toxic than topotecan and conventional doxorubicin, however side effects such as palmar-plantar erythrodysesthesia (PPE) may lead to sub-optimal drug exposure and treatment discontinuation. Methods: A nursing support program was created to determine if patient education and proactive nursing care could improve treatment outcomes by decreasing the occurrence and/or severity of PLD-related side effects. Patients who agreed to participate in the program were: educated about potential toxicities associated with PLD, received written instructions on the prevention and management of side effects and were provided with a diary to record symptoms and interventions. Results: A total of 112 ovarian cancer patients who relapsed after one or more prior therapies were accrued in 8 different centers. PLD was administered as 2nd, 3rd and ≥ 4th line therapy in 51%, 34% and 15% of patients, respectively. The majority of patients (85%) received a Taxol/platinum combination as 1st line therapy. The median patient age was 62 years (32–87). The average dose of PLD was 40.4 mg/m2 (35–50) every 28 days for an average of 4.01 cycles (1–23). Efficacy was evaluated using clinical symptoms and/or radiological evaluation. A majority of patients (69%) benefited from therapy characterized as disease stabilization or better. Overall the frequency of adverse events, in these heavily pretreated patients, was similar to that observed in a previous phase III clinical trial (Gordon JCO 2001) where patients had received only one prior therapy. However, the incidence of some grade 3/4 toxicities was substantially decreased, thus grade 3/4 PPE and mucositis were reduced from 21% to 4% and 8% to 3%, respectively. Conclusions: The nursing support program helped to reduce the severity of PPE and mucositis in patients receiving PLD for recurrent epithelial ovarian cancer. No significant financial relationships to disclose.
Catastrophic Antiphospholipid Syndrome Triggered by Fulminant Chikungunya Infection in a Patient With Systemic Lupus Erythematosus
Authors: Juan‐Felipe Betancur, Erika Paola Navarro, José Humberto Bravo Bonilla, Armando Daniel Cortés, Juan Diego Vélez, Alex Echeverry, Juan‐Pablo Suso, Carlos A. Cañas, Gabriel J. Tobón
Journal: Arthritis & Rheumatology (2016)

The patient, a 21-year-old woman, was admitted to the intensive care unit with a 4-day history of fever, arthritis of the hands and feet, oli-
guria with anasarca, diarrhea, and widespread skin rash. Systemic lupus erythematosus had been diagnosed 5 years previously. She was
positive for lupus anticoagulant and anticardiolipin antibody but had no history of thrombotic or obstetric manifestations. Laboratory
tests for infection and immunologic or biochemical abnormalities were performed and, based on multiple abnormal findings, treatment
with broad-spectrum antibiotics was instituted.
Second cancers following pediatric Hodgkin's disease.
Authors: S L Wolden, K R Lamborn, S F Cleary, D J Tate, S S Donaldson
Journal: Journal of Clinical Oncology (1998)

PURPOSE To define the magnitude of second cancer risk among pediatric Hodgkin's disease survivors and to determine which factors influence this risk. PATIENTS AND METHODS At Stanford,694 children and teenagers were monitored for 1 to 31.6 years (mean, 13.1) after treatment for Hodgkin's disease. Relative risks (RRs), actuarial risks, and absolute excess risks for second malignancies were calculated. The influences of sex, age, stage, splenectomy, treatment and relapse were assessed by multivariate analysis. RESULTS Fifty-six patients developed 59 secondary malignancies: 48 solid tumors, eight leukemias, and three non-Hodgkin's lymphomas. The RR of developing a second cancer was 15.4 (95% confidence interval [CI], 10.6 to 21.5) for females and 10.6 (95% CI, 6.6 to 16.0) for males. Breast cancer (n = 16) and sarcoma (n = 13) were the most common solid tumors. The actuarial risk at 20 years follow-up evaluation was 9.7% for males, 16.8% for females, and 9.2% for breast cancer. The median interval to diagnosis of a second malignancy was shortest for leukemia, 4.3 years, and longest for lung cancer, 18.4 years. Relapse of Hodgkin's disease increased the risk of second malignancy (hazards ratio [HR] = 2.6, P &lt; .001). Hodgkin's disease stage, patient age, splenectomy, and treatment modality did not appear to alter overall risk, although chemotherapy was associated with subsequent leukemia. CONCLUSION Aggressive Hodgkin's disease therapy is successful, but patients have a significant risk of second malignancy. Newer treatment programs focus on obtaining a relapse-free cure of Hodgkin's disease with judicious use of radiation and alkylating agent chemotherapy. Survivors of pediatric Hodgkin's disease require lifelong evaluation and cancer screening.
Increased Clearance Explains Lower Plasma Levels of Tissue-Type Plasminogen Activator by Estradiol: Evidence for Potently Enhanced Mannose Receptor Expression in Mice
Authors: Mirian Lansink, Miek Jong, Martin Bijsterbosch, Marian Bekkers, Karin Toet, Louis Havekes, Jef Emeis, Teake Kooistra
Journal: Blood (1999)